Drug
Nbi 77860
Nbi 77860: highest development phase Phase 1, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-77860 NCT02349503 | Phase 1 | Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow Nbi 77860 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.